Pfizer CEO Can’t “Distinguish Between the Policies” of Donald Trump and Hillary Clinton
https://theintercept.com/2016/06/08/pfizer-trump-clinton/
But both candidates have a complicated record and have previously backed efforts supported by the healthcare industry. In the Senate, Clinton supported legislation that extended the data exclusivity period for biologic drugs, making it harder to bring cheaper generic drugs to market. Trumps healthcare policy plan includes an idea to turn Medicaid into a block grant, meaning states may shift money allocated for healthcare to other priorities.
In Congress, the choice is more clear, as Republican leadership, along with a number of business-friendly Democrats, have relentlessly attacked cost-saving measures that might cut into the profits of drug companies. Legislators have pushed repeatedly to repeal the Independent Payment Advisory Board, a part of the Affordable Care Act designed to rein in healthcare costs by studying best practices, and in recent weeks, have pressured the Obama administration to stop a new trial to find cost-savings for Medicare Part B drugs.